WO2026040951 - BTK-TARGETED PROTEOLYSIS TARGETING CHIMERA COMPOUND, COMPOSITION CONTAINING COMPOUND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/040951
Publication Date
26.02.2026
International Application No.
PCT/CN2025/115291
International Filing Date
18.08.2025
Title **
[English]
BTK-TARGETED PROTEOLYSIS TARGETING CHIMERA COMPOUND, COMPOSITION CONTAINING COMPOUND AND USE THEREOF
[French]
COMPOSÉ CHIMÈRE DE PROTÉOLYSE CIBLÉE DE BTK, COMPOSITION CONTENANT LE COMPOSÉ ET UTILISATION ASSOCIÉE
[Chinese]
靶向BTK蛋白降解靶向嵌合体类化合物及其组合物及用途
Applicants **
SHENZHEN TARGETRX CO., LTD.
Inventors
WANG, Yihan
LI, Huanyin
AI, Yixin
Priority Data
202411140990.9
19.08.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6023 | |
| EPO | Filing, Examination, Granting | 90980 | |
| Japan | Filing, Examination, Granting | 4545 | |
| South Korea | Filing, Examination, Granting | 7170 | |
| USA | Filing, Examination, Granting | 22590 |
Total:
131,308
Contact Us
Abstract[English]
The present invention relates to a compound of formula (I), or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, a pharmaceutical composition containing the compound and a use thereof in treating and/or preventing BTK-related diseases.[French]
La présente invention concerne un composé de formule (I), ou un tautomère, un stéréoisomère, un promédicament, une forme cristalline, un sel, un hydrate ou un solvate pharmaceutiquement acceptable de celui-ci, une composition pharmaceutique contenant le composé et une utilisation de celui-ci dans le traitement et/ou la prévention de maladies associées à BTK.[Chinese]
涉及式(I)的化合物，或其互变异构体、立体异构体、前药、晶型、药学上可接受的盐、水合物或溶剂合物，及其药物组合物和它们在治疗和/或预防BTK相关疾病中的用途。